Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab

Cancer Biomarkers(2024)10.3233/cbm-230431Source: DataRank Database

Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab is a research paper published in Cancer Biomarkers (2024). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.22)OA: hybridTopics (48)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (22)

Sunyoung S. Lee ORCID,Tarık Demir ORCID,Shadi Chamseddine ORCID,Zishuo Ian Hu,Lianchun Xiao ORCID

Live enrichment

PubMed:39269823 PMC:PMC11491993 OpenAlex:https://openalex.org/W4402514633

NCI NIH HHS

Grant: P50 CA217674

NCI NIH HHS

Grant: R01 CA244845

FWCI

2.22

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.3233/cbm-230431

publisherhttps://doi.org/10.3233/cbm-230431

publisherhttps://journals.sagepub.com/doi/pdf/10.3233/CBM-230431

publisherhttps://journals.sagepub.com/doi/full-xml/10.3233/CBM-230431

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39269823

Fields of Study

Cancer Genomics and DiagnosticsHepatocellular Carcinoma Treatment and PrognosisCancer Cells and MetastasisHumansMaleCirculating Tumor DNANivolumabFemaleLiver NeoplasmsAgedBiomarkers, TumorCarcinoma, HepatocellularMiddle AgedPrognosisAged, 80 and overMutationAntineoplastic Agents, ImmunologicalAdult

MeSH Terms

Circulating Tumor DNAAntineoplastic Agents, ImmunologicalNivolumabAdultAgedAged, 80 and overFemaleCarcinoma, HepatocellularHumansLiver NeoplasmsMaleMiddle AgedMutationPrognosisBiomarkers, Tumor

Keywords

MedicineNivolumabHepatocellular carcinomaOncologyInternal medicineProgression-free survivalBiomarkerProportional hazards modelUnivariate analysisOverall survivalCancerMultivariate analysisImmunotherapyBiologyctDNA

Sustainable Development Goals

SDG 0: Good health and well-being